Maravai Lifesciences Holdings (MRVI) EBIT (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly EBIT of -$2.2 million for Q1 2026, up 95.61% year-over-year from -$1.1 million in Q1 2025, and up 96.33% quarter-over-quarter from -$58.8 million in Q4 2025.
Maravai Lifesciences Holdings (MRVI) EBIT (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' EBIT history runs 7 years deep, the most recent figure standing at -$2.2 million for Q1 2026.
- In Q1 2026, EBIT rose 95.61% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$168.3 million (up 36.72% YoY), while the FY2025 annual figure was -$215.3 million, up 8.64% from the prior year.
- EBIT for Q1 2026 stood at -$2.2 million, up from -$58.8 million in the prior quarter.
- The five-year high for EBIT was $180.7 million in Q2 2022, with the low at -$165.6 million in Q3 2024.
- The 5-year median for EBIT is -$13.4 million (2024), against an average of $5.3 million.
- The sharpest annual moves came in 2024 and 2026: EBIT slumped 974.23% in 2024, then surged 95.61% in 2026.
- Maravai Lifesciences Holdings' EBIT stood at $109.2 million in 2022, then plunged by 106.54% to -$7.2 million in 2023, then tumbled by 427.3% to -$37.7 million in 2024, then plunged by 55.95% to -$58.8 million in 2025, then soared by 96.33% to -$2.2 million in 2026.
- Business Quant data shows MRVI's EBIT at -$2.2 million in Q1 2026, -$58.8 million in Q4 2025, and -$41.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | -15.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.09 Mn |
| Mar 31, 2026 | -2.16 Mn |
| Dec 31, 2025 | -58.80 Mn |
| Sep 30, 2025 | -41.03 Mn |
| Jun 30, 2025 | -66.28 Mn |
| Mar 31, 2025 | -49.16 Mn |
| Dec 31, 2024 | -37.70 Mn |
| Sep 30, 2024 | -165.61 Mn |
| Jun 30, 2024 | -13.44 Mn |
| Mar 31, 2024 | -18.86 Mn |
| Dec 31, 2023 | -7.15 Mn |
| Sep 30, 2023 | -15.42 Mn |
| Jun 30, 2023 | -11.61 Mn |
| Mar 31, 2023 | 2.53 Mn |
| Dec 31, 2022 | 109.25 Mn |
| Sep 30, 2022 | 116.90 Mn |
| Jun 30, 2022 | 180.70 Mn |
| Mar 31, 2022 | 167.37 Mn |
| Dec 31, 2021 | 154.54 Mn |
| Sep 30, 2021 | 155.38 Mn |